Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of intravenous antibiotic therapy for cystic fibrosis exacerbations with chronic Pseudomonas aeruginosa infection
2009-014042-28Phase 4Unknown
- Sponsor
- Imperial College London
- Start
- Oct 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of meropenem, ceftazidime and tobramycin in cystic fibrosis (CF) and Pseudomonal infection (2 arms), sponsored by Imperial College London. Primary endpoints: Treatment success or failure at completion of antibiotic course and Time to next exacerbation. Status: unknown.
02
Drugs
meropenemceftazidimetobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2009-014042-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014042-28.